P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales: Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009794/
http://dx.doi.org/10.1097/01.HS9.0000829596.42296.29
_version_ 1784687341033488384
author Popat, R
Usmani, S
Garfall, A
van de Donk, N
Nahi, H
San-Miguel, J
Oriol, A
Nooka, A
Martin, T
Rosinol, L
Chari, A
Karlin, L
Benboubker, L
Mateos, M
Bahlis, N
Moreau, P
Besemer, B
Martínez-López, J
Sidana, S
Pei, L
Trancucci, D
Verona, R
Girgis, S
Olyslager, Y
Jaffe, M
Uhlar, C
Stephenson, T
Van Rampelbergh, R
Banerjee, A
Goldberg, J
Kobos, R
Krishnan, A
author_facet Popat, R
Usmani, S
Garfall, A
van de Donk, N
Nahi, H
San-Miguel, J
Oriol, A
Nooka, A
Martin, T
Rosinol, L
Chari, A
Karlin, L
Benboubker, L
Mateos, M
Bahlis, N
Moreau, P
Besemer, B
Martínez-López, J
Sidana, S
Pei, L
Trancucci, D
Verona, R
Girgis, S
Olyslager, Y
Jaffe, M
Uhlar, C
Stephenson, T
Van Rampelbergh, R
Banerjee, A
Goldberg, J
Kobos, R
Krishnan, A
author_sort Popat, R
collection PubMed
description
format Online
Article
Text
id pubmed-9009794
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90097942022-04-18 P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Popat, R Usmani, S Garfall, A van de Donk, N Nahi, H San-Miguel, J Oriol, A Nooka, A Martin, T Rosinol, L Chari, A Karlin, L Benboubker, L Mateos, M Bahlis, N Moreau, P Besemer, B Martínez-López, J Sidana, S Pei, L Trancucci, D Verona, R Girgis, S Olyslager, Y Jaffe, M Uhlar, C Stephenson, T Van Rampelbergh, R Banerjee, A Goldberg, J Kobos, R Krishnan, A Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9009794/ http://dx.doi.org/10.1097/01.HS9.0000829596.42296.29 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Poster
Popat, R
Usmani, S
Garfall, A
van de Donk, N
Nahi, H
San-Miguel, J
Oriol, A
Nooka, A
Martin, T
Rosinol, L
Chari, A
Karlin, L
Benboubker, L
Mateos, M
Bahlis, N
Moreau, P
Besemer, B
Martínez-López, J
Sidana, S
Pei, L
Trancucci, D
Verona, R
Girgis, S
Olyslager, Y
Jaffe, M
Uhlar, C
Stephenson, T
Van Rampelbergh, R
Banerjee, A
Goldberg, J
Kobos, R
Krishnan, A
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_full P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_fullStr P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_full_unstemmed P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_short P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_sort p06: updated results from the phase 1/2 majestec-1 study of teclistamab, a b-cell maturation antigen x cd3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009794/
http://dx.doi.org/10.1097/01.HS9.0000829596.42296.29
work_keys_str_mv AT popatr p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT usmanis p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT garfalla p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT vandedonkn p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT nahih p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT sanmiguelj p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT oriola p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT nookaa p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT martint p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT rosinoll p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT charia p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT karlinl p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT benboubkerl p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT mateosm p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT bahlisn p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT moreaup p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT besemerb p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT martinezlopezj p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT sidanas p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT peil p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT trancuccid p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT veronar p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT girgiss p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT olyslagery p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT jaffem p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT uhlarc p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT stephensont p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT vanrampelberghr p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT banerjeea p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT goldbergj p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT kobosr p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma
AT krishnana p06updatedresultsfromthephase12majestec1studyofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyeloma

Ejemplares similares